An interventional study of Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation and analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team in Idiopathic Short Stature, sponsored by University Hospital, Montpellier. Recruiting at 4 sites in France. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Mucopolysaccharidosis IV with a site in France — 8 open to participants now, 8 under way, 1 of them phase 3. Mucopolysaccharidosis IV · France.
Among the 19 studies in Mucopolysaccharidosis IV with a site in France, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 with no phase, and was the 13th registered.
101 studies on the registry are indexed under Mucopolysaccharidosis IV; 27 are open to participants now.
Browse Mucopolysaccharidosis IV studies →8 of the 19 studies in Mucopolysaccharidosis IV with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 18+
QED Therapeutics, a BridgeBio company · Sites in France, United States, Australia and 7 more countries
Ages 30 mo–16 yrs
Innoskel · Sites in France, Spain
Ages up to 12
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
QED Therapeutics, a BridgeBio company · Sites in France, United States, Australia and 7 more countries
Ages 3–18
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 20 Mucopolysaccharidosis IV studies recruiting now, 9 (45%) set no upper age limit and 7 (35%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 4 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 5
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 61 across 56 interventional studies indexed under Mucopolysaccharidosis IV.
Median enrollment 135 across the 11 interventional studies, 236 across the 8 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 10 most frequent:
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
University Hospital, Montpellier has 1 study filed under Mucopolysaccharidosis IV — fewer than ten, so there is no comparison to draw.
4 of the studies in Mucopolysaccharidosis IV with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06873035Phase 3QED Therapeutics, a BridgeBio companyAn Interventional Study of Infigratinib in Children With Hypochondroplasia | 2027-01 |
| NCT06036693Institut National de la Santé Et de la Recherche Médicale, FranceMPS (RaDiCo Cohort) (RaDiCo-MPS) | 2026-12 |
| NCT05408715InnoskelA Natural History Study in Children With a Type II Collagen Disorder With Short Stature | 2026-12-31 |
| NCT06675097University Hospital, AngersAssessment of the Impact of Intestinal Gas Emission Quality on the Postoperative Course After Abdominal Surgery | 2027-01-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Mucopolysaccharidosis IV with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial aims to evaluate the prevalence of idiopathic short stature among children whose growth is above -2,5SD (AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or above -2SD of the parental target size (taking child gender into account), after exclusion of classical pediatric and endocrinologic pathologies, and to evaluate the prevalence of monogenic causes of idiopathic short stature. A two-step study will be performed. The first one consists in a standardized multidisciplinary clinico-radiological evaluation of those children to evaluate the real prevalence of idiopathic short stature (ISS) among these patients. The second step consists in performing a whole genome sequencing analysis in the 30 first patients for whom the diagnosis of ISS is confirmed.
Detailed description: Establishing the etiological diagnosis of short stature is an important step to guide the therapeutic management of patients and to propose appropriate genetic counseling. Short stature can be a symptom of many pathologies. However, in the majority of cases (80%), no specific etiology is found during a pediatric clinical investigation. In this case, the diagnosis of "idiopathic" short stature is performed. However, the diagnostic and therapeutic management of short stature after exclusion of classical pediatric causes is extremely heterogeneous and there are currently no consensual recommendations. A substantially higher proportion of diagnosed patients is therefore expected, along with more standardized clinical and genetic procedures. Additionally, in recent years, new methods of genetic investigation (gene panel, whole exome or whole genome sequencing analysis) have made it possible to identify many genetic variants associated with apparently isolated short stature. So far, none of the publications reporting next-generation sequencing analysis have focused on patients with authentic idiopathic short stature, i.e. without associated bone anomalies or syndromic features, and are often focused on only a subset of target genes.
This trial aims at estimating the prevalence of idiopathic short stature among children whose growth is above -2,5SD (AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or above -2SD of the parental target size, after exclusion of classical pediatric and endocrinologic pathologies, and to evaluate the prevalence of monogenic causes of idiopathic short stature. A two-step study will be performed. The first one consists in a multidisciplinary clinico-radiological evaluation of those children to evaluate the real prevalence of idiopathic short stature (ISS) among these patients. The second step consists in performing a whole genome sequencing analysis in the 30 first patients for whom the diagnosis of authentic ISS is confirmed.
All patients will have:
This analysis will assign patients to the diagnosis of either:
A teleconsultation (1) to explain to the parents the conclusions of the multidisciplinary clinico-radiological evaluation.
This teleconsultation will be followed for all patients in the "non-idiopathic short stature" group, by a visit to take samples for genetic analysis in the context of clinical care, followed by a teleconsultation (2) to give them and explain the results
This teleconsultation will be followed for the first 30 patients in the "authentified idiopathic short stature" group, by a visit to take samples for whole genome analysis in the context of research, followed by a teleconsultation (2) to return the results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 patients with apparently idiopathic short stature,
Diagnostic Test: Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation · Procedure: analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team · Genetic: Whole genome analysis for authentified idiopathic short stature
1. pre-inclusion consultation 2. inclusion consultation * personal history * height, weight, cranial perimeters, and spans of both parents * clinical examination of the child * photographs of the child * additional X-rays
multidisciplinary team (geneticist, orthopedist, radiologist, pediatric endocrinologist) which will assign each patient an orientation: * either to the non idiopathic short stature group (syndromic diagnostic orientation or to a constitutional bone pathology) * or to the authentified idiopathic short stature group
For the first 30 patients included in the authentified idiopathic short stature group, a whole genome analysis in trio (child + parents) will be performed as part of the research. For these 30 patients in the authentified idiopathic short stature group, the teleconsultation carried out for the submission of the multidisciplinary consultation meeting conclusions will make it possible to establish the family tree, to explain the interest and limits of the analysis, and to submit the consents dedicated to the genetic analysis.
proportion of patients with authentified idiopathic short stature after multidisciplinary clinical-radiological analysis
Primary endpoint: The primary outcome is the proportion of patients with authentified idiopathic short stature after multidisciplinary clinical-radiological analysis (including geneticist, orthopedist, pediatric endocrinologist, radiologist) performed during a dedicated Multidisciplinary Consultation Meeting (MCM)
Time frame: 3 years
Genome positivity rate
Genome positivity rate (positive diagnosis of pathogenic variation or probably pathogenic variation variants involved in the phenotype) in the group of 30 patients with authentified idiopathic short stature patients in whom the genome analysis was performed
Time frame: 3 years
Rate of positivity of molecular analyses prescribed as part of the care following the PCR
Rate of positivity of molecular analyses prescribed as part of the care following the PCR (positive diagnosis of pathogenic or probably pathogenic variants involved in the phenotype) for patients with non-idiopathic short stature
Time frame: 3 years
Rate of modification of management by the results of genome analysis
Rate of modification of management by the results of genome analysis in the group of 30 patients with authentified idiopathic short stature in whom genome analysis has been performed
Time frame: 3 years
Type of change in management due to genome analysis results
Type of change in management due to genome analysis results: initiation/withdrawal of treatment, referral to organ specialist for specific multidisciplinary management (patients with authentified idiopathic short stature/ Genome+)
Time frame: 3 years
Rate of change in management by results of molecular analysis
Rate of change in management by results of molecular analysis performed in a patient-care context for those with non-idiopathic short stature
Time frame: 3 years
Type of management modification by molecular analysis resultscare context for those with non-idiopathic short stature
Type of management modification by molecular analysis results: initiation/withdrawal of treatment, referral to organ specialist for specific multidisciplinary management (patients with non-idiopathic short stature).
Time frame: 3 years
Parental satisfaction
Parental satisfaction will be assessed using a Visual Analog Scale (VAS) ranging from 0 to 10, where 0 indicates "not satisfied at all" and 10 indicates "completely satisfied." Higher scores indicate greater parental satisfaction. Assessments will be conducted following teleconsultations (Teleconsultation 1 and Teleconsultation 2).
Time frame: 3 years
Variants within the same gene identified in at least 2 patients by whole genome analysis
Variants within the same gene identified in at least 2 patients by whole genome analysis in the group of 30 patients with authentified idiopathic short stature in whom genome analysis has been performed
Time frame: 3 years
Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.
Of 19 interventional studies with no phase under Mucopolysaccharidosis IV, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →